{"title":"达格列净的RP-HPLC分析方法建立、验证及强制降解研究。","authors":"Ujwal Chaudhari, Jagdish K Sahu, Payal R Dande","doi":"10.2174/2949681016666230823091112","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Worldwide, it is projected that 285 million individuals have diabetes, and by 2030, this number is expected to climb to 438 million. About 90% of cases of diabetes mellitus are type 2 (T2DM). Insulin sensitizers, such as metformin and thiazolidinediones; insulin secretagogues, such as sulfonylureas and glinides; dipeptidyl peptidase 4 (DPP-4) inhibitors; glucosidase inhibitors, or oral combination therapy are currently available treatments for type 2 diabetes. Some of these drugs exhibit serious limitations; thus, it is crucial to design an innovative therapy that is efficient and depends on a new channel.</p><p><strong>Aim: </strong>In the current work, a stability-indicating reverse phase HPLC (RP-HPLC) technique was developed and subsequently validated for the detection of dapagliflozin in its API.</p><p><strong>Methods: </strong>The stability-indicating HPLC method for assay included the use of Kromasil 100-5-C8 (100 mm × 4.6 mm) column, UV detector 224 nm, mobile phase composition involving a mixture of acetonitrile:water (52:48), and a flow rate of 1.0 mL/min. ICH guidelines were followed for the method's validation. To assess the method's specificity and stability in showing characteristics, stress degradation studies were carried out. The working standard solution of dapagliflozin was exposed to 1 and 2 N HCl by refluxing 1 and 2 N NaOH with 30% hydrogen peroxide by volume and UV radiation in order to conduct a degradation study.</p><p><strong>Results: </strong>All system suitability parameters were determined to be within the intended ranges, and the drug's retention duration was discovered to be 1.67 minutes. It was also investigated as to how the drug degraded under various circumstances. The drug was discovered to be stable under situations of photolytic, thermal, neutral, alkaline, and oxidative deterioration. The developed stabilityindicating HPLC technique was validated in accordance with ICH Q2 recommendations, and the validation parameters, such as linearity, precision, and robustness, were achieved within the approved standards.</p><p><strong>Conclusion: </strong>It may be concluded that this method is stability-indicating and specific, and it can be successfully applied to analyze tablet dosage forms containing dapagliflozin.</p>","PeriodicalId":72844,"journal":{"name":"Drug metabolism and bioanalysis letters","volume":" ","pages":"140-152"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Analytical Method Development, Validation and Forced Degradation Study of Dapagliflozin by RP-HPLC.\",\"authors\":\"Ujwal Chaudhari, Jagdish K Sahu, Payal R Dande\",\"doi\":\"10.2174/2949681016666230823091112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Worldwide, it is projected that 285 million individuals have diabetes, and by 2030, this number is expected to climb to 438 million. About 90% of cases of diabetes mellitus are type 2 (T2DM). Insulin sensitizers, such as metformin and thiazolidinediones; insulin secretagogues, such as sulfonylureas and glinides; dipeptidyl peptidase 4 (DPP-4) inhibitors; glucosidase inhibitors, or oral combination therapy are currently available treatments for type 2 diabetes. Some of these drugs exhibit serious limitations; thus, it is crucial to design an innovative therapy that is efficient and depends on a new channel.</p><p><strong>Aim: </strong>In the current work, a stability-indicating reverse phase HPLC (RP-HPLC) technique was developed and subsequently validated for the detection of dapagliflozin in its API.</p><p><strong>Methods: </strong>The stability-indicating HPLC method for assay included the use of Kromasil 100-5-C8 (100 mm × 4.6 mm) column, UV detector 224 nm, mobile phase composition involving a mixture of acetonitrile:water (52:48), and a flow rate of 1.0 mL/min. ICH guidelines were followed for the method's validation. To assess the method's specificity and stability in showing characteristics, stress degradation studies were carried out. The working standard solution of dapagliflozin was exposed to 1 and 2 N HCl by refluxing 1 and 2 N NaOH with 30% hydrogen peroxide by volume and UV radiation in order to conduct a degradation study.</p><p><strong>Results: </strong>All system suitability parameters were determined to be within the intended ranges, and the drug's retention duration was discovered to be 1.67 minutes. It was also investigated as to how the drug degraded under various circumstances. The drug was discovered to be stable under situations of photolytic, thermal, neutral, alkaline, and oxidative deterioration. The developed stabilityindicating HPLC technique was validated in accordance with ICH Q2 recommendations, and the validation parameters, such as linearity, precision, and robustness, were achieved within the approved standards.</p><p><strong>Conclusion: </strong>It may be concluded that this method is stability-indicating and specific, and it can be successfully applied to analyze tablet dosage forms containing dapagliflozin.</p>\",\"PeriodicalId\":72844,\"journal\":{\"name\":\"Drug metabolism and bioanalysis letters\",\"volume\":\" \",\"pages\":\"140-152\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug metabolism and bioanalysis letters\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2949681016666230823091112\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and bioanalysis letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2949681016666230823091112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:在全球范围内,预计有2.85亿人患有糖尿病,到2030年,这一数字预计将攀升至4.38亿。约90%的糖尿病病例为2型糖尿病(T2DM)。胰岛素增敏剂,如二甲双胍和噻唑烷二酮类;胰岛素分泌剂,如磺脲类和格列尼德;二肽基肽酶4 (DPP-4)抑制剂;葡萄糖苷酶抑制剂或口服联合治疗是目前治疗2型糖尿病的有效方法。其中一些药物表现出严重的局限性;因此,设计一种高效且依赖于新渠道的创新疗法至关重要。目的:建立稳定性指示反相高效液相色谱(RP-HPLC)技术,并对其原料药中达格列净的检测进行验证。方法:采用HPLC法测定,色谱柱为Kromasil 100-5- c8 (100 mm × 4.6 mm),紫外检测器为224 nm,流动相为乙腈:水(52:48),流速为1.0 mL/min。方法的验证遵循ICH指南。为了评估该方法在显示特征方面的特异性和稳定性,进行了应力降解研究。将达格列净工作标准溶液用1和2 N NaOH与30%双氧水按体积回流,在紫外辐射下分别暴露于1和2 N HCl中,进行降解研究。结果:所有系统适宜性参数均在预期范围内,药物滞留时间为1.67 min。还调查了该药物在各种情况下如何降解。该药物在光解、热、中性、碱性和氧化变质的情况下都是稳定的。根据ICH Q2建议对所建立的稳定性指示HPLC技术进行了验证,验证参数如线性、精密度和鲁棒性在批准的标准范围内实现。结论:该方法具有稳定性和专精性,可用于达格列净片剂剂型的分析。
Analytical Method Development, Validation and Forced Degradation Study of Dapagliflozin by RP-HPLC.
Background: Worldwide, it is projected that 285 million individuals have diabetes, and by 2030, this number is expected to climb to 438 million. About 90% of cases of diabetes mellitus are type 2 (T2DM). Insulin sensitizers, such as metformin and thiazolidinediones; insulin secretagogues, such as sulfonylureas and glinides; dipeptidyl peptidase 4 (DPP-4) inhibitors; glucosidase inhibitors, or oral combination therapy are currently available treatments for type 2 diabetes. Some of these drugs exhibit serious limitations; thus, it is crucial to design an innovative therapy that is efficient and depends on a new channel.
Aim: In the current work, a stability-indicating reverse phase HPLC (RP-HPLC) technique was developed and subsequently validated for the detection of dapagliflozin in its API.
Methods: The stability-indicating HPLC method for assay included the use of Kromasil 100-5-C8 (100 mm × 4.6 mm) column, UV detector 224 nm, mobile phase composition involving a mixture of acetonitrile:water (52:48), and a flow rate of 1.0 mL/min. ICH guidelines were followed for the method's validation. To assess the method's specificity and stability in showing characteristics, stress degradation studies were carried out. The working standard solution of dapagliflozin was exposed to 1 and 2 N HCl by refluxing 1 and 2 N NaOH with 30% hydrogen peroxide by volume and UV radiation in order to conduct a degradation study.
Results: All system suitability parameters were determined to be within the intended ranges, and the drug's retention duration was discovered to be 1.67 minutes. It was also investigated as to how the drug degraded under various circumstances. The drug was discovered to be stable under situations of photolytic, thermal, neutral, alkaline, and oxidative deterioration. The developed stabilityindicating HPLC technique was validated in accordance with ICH Q2 recommendations, and the validation parameters, such as linearity, precision, and robustness, were achieved within the approved standards.
Conclusion: It may be concluded that this method is stability-indicating and specific, and it can be successfully applied to analyze tablet dosage forms containing dapagliflozin.